<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00867672</url>
  </required_header>
  <id_info>
    <org_study_id>00332/AMLSG14-09</org_study_id>
    <nct_id>NCT00867672</nct_id>
  </id_info>
  <brief_title>Study of Decitabine Alone or in Combination With Valproic Acid and All-trans Retinoic Acid in Acute Myeloid Leukemia</brief_title>
  <acronym>DECIDER</acronym>
  <official_title>Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients &gt; 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AML of the older patient constitutes a major unmet clinical need since the large majority&#xD;
      will not be found eligible for induction chemotherapy. Reasons for this decision include host&#xD;
      factors (comorbidities, reduced performance status, functional limitations due to age),&#xD;
      leading to often poor tolerance of repeated chemotherapy courses and the unfavorable biology&#xD;
      underlying this disease in older patients. Low dose Decitabine has shown very promising&#xD;
      efficacy in high-risk MDS and is therefore a very promising approach also in older AML&#xD;
      patients. Preliminary results from several centres have demonstrated excellent feasibility&#xD;
      and good efficacy of this treatment. Therefore the investigators intend to investigate the&#xD;
      effects of two drugs added onto low-dose Decitabine which have shown very promising&#xD;
      synergistic effects in vitro and for which preliminary results indicate that the combination&#xD;
      with low-dose Decitabine is very feasible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      By employing a 2x2 factorial design, this phase II study will address the possible added&#xD;
      efficacy of addition of one or even both of these agents to low-dose Decitabine. The primary&#xD;
      endpoint of this study will be objective response rate (complete and partial remissions).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective best response rate (complete remission (CR) and partial remission (PR))</measure>
    <time_frame>12 months after randomization of the last patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall best response rate (CR, PR and antileukemic effect (ALE))</measure>
    <time_frame>12 months after randomization of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>12 months after randomization of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>12 months after randomization of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>until 4 weeks after study drug intake</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and toxicity</measure>
    <time_frame>until 4 weeks after study drug intake</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine+VPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks, and VPA (p.o.) from day 6 of first cycle continuously throughout all treatment cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine+ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Decitabine+VPA+ATRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks and VPA (p.o.) from day 6 continuously throughout all treatment cycles and ATRA (45 mg/m² p.o.), from day 6 to day 28 of each treatment cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks</description>
    <arm_group_label>Decitabine</arm_group_label>
    <arm_group_label>Decitabine+ATRA</arm_group_label>
    <arm_group_label>Decitabine+VPA</arm_group_label>
    <arm_group_label>Decitabine+VPA+ATRA</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VPA</intervention_name>
    <description>VPA starting on day 6 of first cycle continuously throughout all treatment cycles</description>
    <arm_group_label>Decitabine+VPA</arm_group_label>
    <arm_group_label>Decitabine+VPA+ATRA</arm_group_label>
    <other_name>Valproic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATRA</intervention_name>
    <description>ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle</description>
    <arm_group_label>Decitabine+ATRA</arm_group_label>
    <arm_group_label>Decitabine+VPA+ATRA</arm_group_label>
    <other_name>All-trans retinoic acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained according to international guidelines and local law;&#xD;
&#xD;
          2. Male or female patients aged &gt; 60 years without upper age limit;&#xD;
&#xD;
          3. Patients with primary or secondary AML according to WHO (≥ 20% blasts in the&#xD;
             peripheral blood (pB) or bone marrow (BM)) who are not expected to benefit from&#xD;
             standard remission-induction chemotherapy;&#xD;
&#xD;
          4. Patients with &lt; 30 000 leukocytes/μl;&#xD;
&#xD;
          5. Performance status ECOG 0, 1, 2;&#xD;
&#xD;
          6. Creatinine &lt; 2.0 mg/dl (unless leukemia-related);&#xD;
&#xD;
          7. Ability to understand the nature of the study and the study related procedures and to&#xD;
             comply with them.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AML of FAB subtype M3;&#xD;
&#xD;
          2. Previous remission-induction chemotherapy for MDS or AML, previous allografting;&#xD;
&#xD;
          3. Previous treatment with DAC, 5-azacytidine, VPA or another HDAC inhibitor, or ATRA;&#xD;
&#xD;
          4. &quot;Low-dose&quot; chemotherapy (e.g. hydroxyurea, cytosine arabinoside (Ara-C), melphalan,&#xD;
             clofarabine etc.) within 4 weeks prior to DAC treatment, except for cytoreduction of&#xD;
             leukocytosis ≥ 30 000/μl with hydroxyurea or Ara-C as proscribed by the study protocol&#xD;
             (section 7.3 and 7.4); the patient must have recovered from all clinically relevant&#xD;
             reversible non-hematologic toxicities;&#xD;
&#xD;
          5. Treatment with tyrosine kinase inhibitors, immunomodulating agents (IMIDS) or other&#xD;
             investigational AML treatment within the last 4 weeks or in a time period of drug&#xD;
             half-life x 5 (whatever is shorter) before the first administration of DAC;&#xD;
&#xD;
          6. Treatment with cytokines within previous 4 weeks;&#xD;
&#xD;
          7. Concomitant therapy which is considered relevant for the evaluation of efficacy or&#xD;
             safety of the trial drug (i.e. other chemo- or immunotherapy);&#xD;
&#xD;
          8. Other malignancy requiring treatment (previous chemotherapy for other malignancies is&#xD;
             not an exclusion criteria);&#xD;
&#xD;
          9. Cardiac insufficiency NYHA IV;&#xD;
&#xD;
         10. Insufficient hepatic function (bilirubin, AST or ALT &gt; = 2.5 x Upper Limit of Normal&#xD;
             (ULN)) (unless leukemia-related);&#xD;
&#xD;
         11. Fatal hepatic function disorder during treatment with valproic acid in siblings;&#xD;
&#xD;
         12. Hepatic porphyria;&#xD;
&#xD;
         13. Manifest serious pancreatic function disorder;&#xD;
&#xD;
         14. Plasmatic coagulation disorder not related to AML;&#xD;
&#xD;
         15. Known active hepatitis B or C;&#xD;
&#xD;
         16. Known HIV infection;&#xD;
&#xD;
         17. Other uncontrolled active infections;&#xD;
&#xD;
         18. Known allergy against soy beans or peanuts;&#xD;
&#xD;
         19. Psychiatric disorder that interferes with treatment;&#xD;
&#xD;
         20. Patient without legal capacity who is unable to understand the nature, significance&#xD;
             and consequences of the study;&#xD;
&#xD;
         21. Known hypersensitivity to, or intolerance of, one of the trial drugs, another retinoid&#xD;
             or the excipients of the trial drugs;&#xD;
&#xD;
         22. Concomitant use of any other investigational drug or participation in a clinical trial&#xD;
             within the last thirty days before the start of this study; simultaneous participation&#xD;
             in registry and diagnostic trials is allowed;&#xD;
&#xD;
         23. Female patients who are pregnant or breast feeding;&#xD;
&#xD;
         24. Fertile patients refusing to use safe contraceptive methods during the study (for&#xD;
             details see clinical trial protocol section 5.3);&#xD;
&#xD;
         25. Known or persistent abuse of medication, drugs or alcohol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Lübbert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology/Oncology, University of Freiburg Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum der Technischen Universität Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIAKO Ev. Diakonie-Krankenhaus gGmbH</name>
      <address>
        <city>Bremen</city>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen GmbH</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien-Hospital Hagen</name>
      <address>
        <city>Hagen</city>
        <zip>58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm gGmbH</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med. Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Lahr-Ettenheim</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caritas Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU München</name>
      <address>
        <city>München</city>
        <zip>86175</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Münster Medical Center</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Onkologie Ravensburg</name>
      <address>
        <city>Ravensburg</city>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eberhard Karls Universität Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Villingen-Schwenningen</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://bmccancer.biomedcentral.com/articles/10.1186/s12885-015-1432-5</url>
    <description>Study protocol publication</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>August 30, 2016</last_update_submitted>
  <last_update_submitted_qc>August 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Michael Luebbert</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Low-dose Decitabine</keyword>
  <keyword>Valproic acid</keyword>
  <keyword>All-trans retinoic acid</keyword>
  <keyword>Older Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

